Zoafin ( Auranofin 1mg)
For veterinarians that are looking for a break through.
You may not have studied about this new technology in veterinary school but this is going to change the way you treat protozoa and gram positive bacterial infections. Doses 10 to 16 fold less than current antibiotics, no resistance, cysts and trophozoite treatment and the safety and toxicological data you are looking for. A broad spectrum of protozoal efficacy has been indicated by studies attached.
A brief look in the formulary will not give you the correct information for Zoafin ( 1-6mg Auranofin for 5 days) ,at these doses and duration the safety has been proven by a number of investigators , see attached articles, this is supported by further testing and in the FDA approval process.
What does the science indicate and how can we help more animals ?
The first approved drug for Giardiasis may be around the corner but you can get it now.
Los Angeles - January 2019 - After gaining an Innovation Waiver from the FDA Centers of Veterinary Medicine for the treatment of Giardisasis in cats and dogs, an NIH sponsored PhaseII (A) clinical trial for humans, Subrimed inc and its CEO, Dr Brian Paul are set to bring Zoafin to veterinary practices.
As with many off-label drugs vets prescribe, flagyl and panacur are not approved for treating Giardiasis in companion animals and there are problems with toxicity and resistance.
The FDA Centers of Veterinary Medicine Innovation status attained by our technology was a two year process, in which data across 5 species including toxicological data, that showed that at these doses and duration Auranofin is not toxic or mutagenic and the low absorption resulted in no trace of the drug in the blood or organs. We currently have efficacy trial data in cats and dogs. The active ingredient in this case is particularly interesting, it is a thioredoxin reductase enzyme inhibitor.
Current Protein and Peptide Science, 2014, 15, 621-646 621 Thioredoxin Reductase and its Inhibitors.
Thioredoxin plays a crucial role in a wide number of physiological processes, which span from reduction of nucleotides to deoxyriboucleotides to the detoxification from xenobiotics, oxidants and radicals. The redox function of Thioredoxin is critically dependent on the enzyme Thioredoxin NADPH Reductase (TrxR). In view of its indirect involvement in the above mentioned physio/pathological processes, inhibition of TrxR is an important clinical goal.
We all remember NAD and NADH from cell biology and physiology but fewer of us remember thioredoxin reductase enzyme. The fact that protozoa and some malignant or virally infected mammalian cells and gram+ve pathogens are specifically susceptible to the inhibition of the TrxR enzyme makes it a valuable drug target. The ability to cause protozoal apoptosis, has resulted in it being very promising in the management of aero tolerant protozoa, Trichonomas, Cryptosporidium, Giardia, Etomeba hystolitica, and Microsporidium , Toxoplasma gondin, Tryponosom brucei Leishomania infortum, Schistomosis. Gram positive bacterial studies have shown promise also, MRSA by inhibiting cell protein synthesis, cell wall and DNA of S Aureus, E.faecum, E. feacalis, S. pneumonia, S. agalactiae, C. difficle, T denticola, effective in concentrations 16 fold lower than vancomycin or methicillin. Great promise combining with ciproflaxin, Gentamicin and Linezolid.
The Phase I and now Phase IIa human trials have produces exciting results for the treatment of protozoa, with good safety and no toxicity and no mutagenic data resulting, see attached articles in menu, add to this the anti-fungal inhibiting the Mia40-Erv1 pathway data and this is a promising new class of drug, low dose, high safety and a wide spectrum of activity
Subrimed’s social Pharma initiative “Cure without Cost” may benefit veterinarians that treat animals in shelters, with free drugs being provided to co-operating non-profits.